The purpose of this study was to assess whether a new drug, Nulojix® (belatacept), would
minimize serious long term side effects associated with anti-rejection medications while
still protecting the new kidney from damage. The researchers also wanted to learn more about
the safety of this treatment and long term health of the transplanted kidney.